报价延迟最少15分钟:2026/04/21 23:58 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.37 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.20/-1.20
|
|
企业价值
41.36M
|
| 资产负债 |
|
每股账面净值
2.31
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
16.89M
|
|
每股收益
0.94
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study. |
